Credit Suisse is shutting its cash equity sales business in Japan and has told hedge funds and other institutional clients it would no longer be taking orders as UBS Group AG proceeds with a global overhaul.
This content was published on
2 minutes
Bloomberg
A number of staff in Tokyo are leaving as part of the process, according to people with knowledge of the matter. Credit Suisse’s investment bank arm has already exited from stock underwriting in the country, the people said, declining to be identified as the deliberations are private. Both UBS and Credit Suisse declined to comment.
The purchase of Credit Suisse has increased UBS’s workforce to about 120,000, which Switzerland’s largest bank intends to ultimately cut by about 30%, Bloomberg has reported, and it’s considering slashing two-thirds of investment bankers in Asia-Pacific.
The Japanese securities unit had 421 employees as of March this year, according to local filings. It has also been offering foreign exchange trading among other services such as wealth management. It is unclear about the fate of Credit Suisse’s other businesses in the country.
UBS has shown little appetite for Credit Suisse’s investment bank since the government-brokered deal was announced in March. The bank said it would continue its own strategy of a smaller capital-lite securities unit and would only use Credit Suisse’s investment bank to reinforce their global business while managing the rest down. The bank has said it aims to reduce staff costs by about $6 billion (CHF5.25 billion) over the next several years.
UBS is due to release more detailed information around its strategy along with second-quarter results for the combined banks on August 31. This month, UBS announced that it was terminating an agreement with the Swiss government in which the state guaranteed up to $10 billion of losses that could stem from the acquisition of Credit Suisse assets.
Popular Stories
More
Culture
Wealth is not all: how gentrification in Zurich has led to housing shortage
Novo Nordisk stock market plunge drags down Swiss device maker Ypsomed
This content was published on
The Danish pharmaceutical giant, Novo Nordisk, faced setbacks on Friday that weighed on the share price of Swiss injection device manufacturer Ypsomed.
Swiss press react to EU deal with mix of euphoria and scepticism
This content was published on
Swiss media reaction to the agreement between Switzerland and the EU varies widely. Some are celebrating, while others worry about what is to come.
Swiss Solidarity donations to tackle child abuse top CHF4 million
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has raised over CHF4 million ($4.3 million) to tackle child abuse.
EU Commission president says Swiss-EU deal is ‘historic’ agreement
This content was published on
At a joint media conference with Swiss President Viola Amherd in Bern, European Commission President Ursula von der Leyen spoke of a "day of joy".
Switzerland and EU reach deal on future bilateral relations
This content was published on
Switzerland and the European Union have announced a political agreement to update their trading relationship after almost a decade of difficult talks.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.